HUS-epidemin sommaren 2011 var allvarlig: Tyska och svenska erfarenheter av EHEC-utbrottet

Lakartidningen

Volumn 109, Issue 25, 2012, Pages 1230-1234

  Samuelsson, Ola ^a   Follin, Per ^b   Rundgren, Malin ^b   Rylander, Christian ^c   Selga, Daina ^d   Ståhl, Agneta ^e  

^a Universitetssjukhuset   (Sweden)

^b Smittskyddsenheten i Västra Götalandsregionen ^*  (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Njurmedicin   (Sweden)

^e Njurmedicin   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; DISEASE COURSE; EPIDEMIC; ESCHERICHIA COLI INFECTION; FEMALE; GERMANY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; MIDDLE AGED; NOTE; PLASMAPHERESIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE OUTBREAKS; DISEASE PROGRESSION; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PLASMAPHERESIS; SHIGA-TOXIGENIC ESCHERICHIA COLI; SWEDEN;

EID: 84863908011     PISSN: 00237205     EISSN: 16527518     Source Type: Journal    
DOI: None     Document Type: Note

References (27)

1. The German EHEC-HUS Registry. The German 2011 epidemic of Shiga toxin-producing E. Coli-the nephrological view. Nephrol Dial Transplant. 2011;26:2723-6.
2. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis. 2011;11(9):671-6.
3. Frank C, Werber D, Cramer JP, et al; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365(19):1771-80.
4. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escheria coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-86.
5. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, haemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831-46.
6. Parry SM, Salmon RL. Sporadic STEC O157 infection: Secondary household transmission in Wales. Emerg Infect Dis. 1998;4(4):657-61.
7. Karpman D. Hemolytiskt uremiskt syndrom och trombotisk trombocytopen purpura. Nya rön om EHEC, komplementmutationer och ADAMTS13. Läkartidningen. 2008;105:1098-101.
8. Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med. 2011;365:1763-70.
9. European Food Safety Authority Tracing seeds, in particular fenugreek (Trigonella foenumgraecum) seeds, in relation to the Shiga toxin-producing E. coli (STEC) O104:H4 2011 outbreaks in Germany and France. Parma: EFSA; 2011. Technical report.
10. Kielstein JT. An analysis of 600 patients from the German EHECHUS registry. Personligt meddelande.
11. Besbas N, Karpman D, Landau D, et al; European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70(3):423-31.
12. Ruggenenti P, Remuzzi G. A German outbreak of haemolytic uraemic syndrome. Lancet. 2011;378(9796):1057-8.
13. Weissenborn K. Neurological findings in HUS cases caused by EHEC O104:H4. Oral presentation at EHEC/HUS Symposium, Deutsche Gesellschaft für Nephrologie, DGfN, Berlin, 9 september 2011.
14. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: A meta-analysis. JAMA. 2002 Aug 28;288(8):996-1001.
15. Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006;24(5):731-42.
16. Haller HG. Epidemiology/Bacteriology of HUS: Immunoadsorption SHIGA Toxin as a New Treatmetn Option. Muntlig presentation. Kidney Week. American Society of Nephrology, Philadelphia, PA.USA. 2011-11-11.
17. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354(9187):1327-30.
18. Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytpenic pupura. Cochrane Database Syst Rev. 2009;(1): CD003595.
19. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364(26):2561-3.
20. Advice of the German Society of Nephrology on the use of Eculizumab during the 2011 EHEC HUS outbreak 04.06.11. http://www. ehec-register.de/index.php?id= 325&L=1
21. Stahl RA. Eculizumab experience in HUS. Muntlig presentation. Kidney Week. American Society of Nephrology, Philadelphia, PA.USA. 2011-11-11.
22. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs. 2002;3(7):1017-23.
23. Röth A, Dührsen U. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur J Haematol. 2011 Dec;87(6):473-9.
24. Waters AM, Licht C. aHUS caused by complement dysregulation: New therapies on the horizon. Pediatr Nephrol. 2011 Jan;26(1):41-57.
25. The world's most expensive drugs. http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html.
26. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182(10):6394-400.
27. Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117(20):5503-13.